Drug Trial Radar · NCT06333951
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
49
Actual
Start
Sep 17, 2024
Primary completion
Oct 31, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Mar 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.
Conditions
- Thoracic Tumors
- Non-small Cell Lung Cancer
Interventions
AnvumetostatDrug
Administered PO
CarboplatinDrug
Administered IV
PaclitaxelDrug
Administered IV
PembrolizumabDrug
Administered IV
PemetrexedDrug
Administered IV
SotorasibDrug
Administered PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Dose Limiting Toxicities (DLT)Time frame: Up to approximately 21 days
- Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)Time frame: Up to approximately 3 years
- Number of Participants Experiencing Serious Adverse Events (SAE)Time frame: Up to approximately 3 years
Locations
83 sites in 20 countries. Site status is shown where the registry gives one.
Comprehensive Blood and Cancer Center
Bakersfield, California
City of Hope National Medical Center
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center
Duarte, California
Translational Research in Oncology US Inc, Trio Central Pharmacy
Los Angeles, California
University of California Irvine
Orange, California
University of California Los Angeles
Santa Monica, California
Rocky Mountain Cancer Centers
Denver, Colorado
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut
HealthPartners Institute
Saint Paul, Minnesota
Saint Lukes Hospital of Kansas City
Kansas City, Missouri
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Roswell Park Cancer Institute
Buffalo, New York
New York University Grossman School of Medicine
New York, New York
Perlmutter Cancer Center at New York University Langone Hospital----Long Island
New York, New York
Upstate University Hospital
Syracuse, New York
Hightower Clinical
Oklahoma City, Oklahoma
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
University of Tennessee Medical Center Knoxville
Knoxville, Tennessee
United States Oncology Regulatory Affairs Corporate Office
Nashville, Tennessee
Texas Oncology - Dallas Fort Worth
Dallas, Texas
US Oncology Research Investigational Products Center
Dallas, Texas
Oncology Consultants Cancer Center
Houston, Texas
Texas Oncology Northeast Texas
Tyler, Texas
Virginia Cancer Specialists PC
Fairfax, Virginia
Northwest Medical Specialties, PLLC
Tacoma, Washington
Cemic
Ciudad Autonoma Buenos Aires, Argentina
Instituto Argentino de Diagnóstico y Tratamiento
Ciudad Automona de Buenos Aires, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Orange Health Service
Orange, New South Wales, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Medizinische Universitaet Graz
Graz, Austria
Medizinische Universitaet Innsbruck
Innsbruck, Austria
Centre Hospitalier Universitaire de Liege - Sart Tilman
Liège, Belgium
Instituto Cancer Sao Paulo Icesp
São Paulo, Brazil
Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda
Ijuí, Rio Grande do Sul, Brazil
Cipo - Centro Integrado de Pesquisa em Oncologia
Porto Alegre, Rio Grande do Sul, Brazil
Fund Faculdade Regional Med Sao Jose Rio Preto
São José do Rio Preto, São Paulo, Brazil
Beneficencia Portuguesa de Sao Paulo - Bp
São Paulo, São Paulo, Brazil
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.